{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T21:39:20Z","timestamp":1780695560880,"version":"3.54.1"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2023,12,1]]},"abstract":"<jats:sec id=\"ab-doi230054-4\"><jats:title>Importance<\/jats:title><jats:p>The incidence of melanoma diagnoses has been increasing in recent decades, and controlled studies have indicated high histopathologic discordance across the intermediate range of melanocytic lesions. The respective causes for these phenomena remain incompletely understood.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230054-5\"><jats:title>Objective<\/jats:title><jats:p>To identify pathologist characteristics associated with tendencies to diagnose melanocytic lesions as higher grade vs lower grade or to diagnose invasive melanoma vs any less severe diagnosis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230054-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This exploratory study used data from 2 nationwide studies (the Melanoma Pathology [M-Path] study, conducted from July 2013 to May 2016, and the Reducing Errors in Melanocytic Interpretations [REMI] study, conducted from August 2018 to March 2021) in which participating pathologists who interpreted melanocytic lesions in their clinical practices interpreted study cases in glass slide format. Each pathologist was randomly assigned to interpret a set of study cases from a repository of skin biopsy samples of melanocytic lesions; each case was independently interpreted by multiple pathologists. Data were analyzed from July 2022 to February 2023.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230054-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The association of pathologist characteristics with diagnosis of a study case as higher grade (including severely dysplastic and melanoma in situ) vs lower grade (including mild to moderately dysplastic nevi) and diagnosis of invasive melanoma vs any less severe diagnosis was assessed using logistic regression. Characteristics included demographics (age, gender, and geographic region), years of experience, academic affiliation, caseload of melanocytic lesions in their practice, specialty training, and history of malpractice suits.<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230054-8\"><jats:title>Results<\/jats:title><jats:p>A total of 338 pathologists were included: 113 general pathologists and 74 dermatopathologists from M-Path and 151 dermatopathologists from REMI. The predominant factor associated with rendering more severe diagnoses was specialist training in dermatopathology (board certification and\/or fellowship training). Pathologists with this training were more likely to render higher-grade diagnoses (odds ratio [OR], 2.63; 95% CI, 2.10-3.30; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) and to diagnose invasive melanoma (OR, 1.95; 95% CI, 1.53-2.49; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) than pathologists without this training interpreting the same case. Nonmitogenic pT1a diagnoses (stage pT1a melanomas with no mitotic activity) accounted for the observed difference in diagnosis of invasive melanoma; when these lesions, which carry a low risk of metastasis, were grouped with the less severe diagnoses, there was no observed association (OR, 0.95; 95% CI, 0.74-1.23; <jats:italic>P<\/jats:italic>\u2009=\u2009.71). Among dermatopathologists, those with a higher caseload of melanocytic lesions in their practice were more likely to assign higher-grade diagnoses (OR for trend, 1.27; 95% CI, 1.04-1.56; <jats:italic>P<\/jats:italic>\u2009=\u2009.02).<\/jats:p><\/jats:sec><jats:sec id=\"ab-doi230054-9\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>The findings suggest that specialty training in dermatopathology is associated with a greater tendency to diagnose atypical melanocytic proliferations as pT1a melanomas. These low-risk melanomas constitute a growing proportion of melanomas diagnosed in the US.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.4334","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T16:01:48Z","timestamp":1699459308000},"page":"1315","source":"Crossref","is-referenced-by-count":10,"title":["Pathologist Characteristics Associated With Rendering Higher-Grade Diagnoses for Melanocytic Lesions"],"prefix":"10.1001","volume":"159","author":[{"given":"Kathleen F.","family":"Kerr","sequence":"first","affiliation":[{"name":"Department of Biostatistics, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Elder","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael W.","family":"Piepkorn","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, University of Washington School of Medicine, Seattle"},{"name":"Dermatopathology Northwest, Bellevue, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevan R.","family":"Knezevich","sequence":"additional","affiliation":[{"name":"Pathology Associates, Clovis, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan M.","family":"Eguchi","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah L.","family":"Shucard","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Reisch","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joann G.","family":"Elmore","sequence":"additional","affiliation":[{"name":"Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond L.","family":"Barnhill","sequence":"additional","affiliation":[{"name":"Department of Translational Research, Institut Curie, Paris, France"},{"name":"UFR of Medicine, University of Paris Cit\u00e9, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"doi230054r1","doi-asserted-by":"publisher","first-page":"j2813","DOI":"10.1136\/bmj.j2813","article-title":"Pathologists\u2019 diagnosis of invasive melanoma and melanocytic proliferations: observer accuracy and reproducibility study.","volume":"357","author":"Elmore","year":"2017","journal-title":"BMJ"},{"issue":"6","key":"doi230054r2","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/cup.v48.6","article-title":"Terminology for melanocytic skin lesions and the MPATH-Dx classification schema: a survey of dermatopathologists.","volume":"48","author":"Radick","year":"2021","journal-title":"J Cutan Pathol"},{"issue":"17","key":"doi230054r3","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1002\/cncr.v127.17","article-title":"Histopathologic synoptic reporting of invasive melanoma: how reliable are the data?","volume":"127","author":"Taylor","year":"2021","journal-title":"Cancer"},{"issue":"2","key":"doi230054r4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/cup.v49.2","article-title":"Characterization of multiple diagnostic terms in melanocytic skin lesion pathology reports.","volume":"49","author":"Chang","year":"2022","journal-title":"J Cutan Pathol"},{"key":"doi230054r5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jdin.2022.06.017","article-title":"Reproducibility of the histopathologic diagnosis of melanoma and related melanocytic lesions: results from a testing study and a reference guide for providers.","volume":"9","author":"Piepkorn","year":"2022","journal-title":"JAAD Int"},{"issue":"1","key":"doi230054r6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1056\/NEJMsb2019760","article-title":"The rapid rise in cutaneous melanoma diagnoses.","volume":"384","author":"Welch","year":"2021","journal-title":"N Engl J Med"},{"issue":"14","key":"doi230054r7","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJMsr1905447","article-title":"Epidemiologic signatures in cancer.","volume":"381","author":"Welch","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"doi230054r8","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1016\/j.jid.2022.03.028","article-title":"Comment on \u201cAn Epidemiologic Analysis of Melanoma Overdiagnosis in the United States, 1975-2017.\u201d","volume":"142","author":"Harms","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"2","key":"doi230054r9","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/(SICI)1096-9098(199802)67:2<73::AID-JSO1>3.0.CO;2-I","article-title":"Non-metastasizing melanoma?","volume":"67","author":"Burton","year":"1998","journal-title":"J Surg Oncol"},{"issue":"4","key":"doi230054r10","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1001\/jamadermatol.2022.0139","article-title":"Estimating overdiagnosis of melanoma using trends among Black and White patients in the US.","volume":"158","author":"Adamson","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"7","key":"doi230054r11","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.jid.2021.12.003","article-title":"An epidemiologic analysis of melanoma overdiagnosis in the United States, 1975-2017.","volume":"142","author":"Kurtansky","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi230054r12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jaad.2011.10.026","article-title":"Increased diagnosis of thin superficial spreading melanomas: a 20-year study.","volume":"67","author":"Frangos","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"doi230054r13","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1001\/jamadermatol.2022.2932","article-title":"Effect of prior diagnoses on dermatopathologists\u2019 interpretations of melanocytic lesions: a randomized controlled trial.","volume":"158","author":"Elmore","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"1","key":"doi230054r16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jaad.2013.07.027","article-title":"The MPATH-Dx reporting schema for melanocytic proliferations and melanoma.","volume":"70","author":"Piepkorn","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi230054r17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jaad.2018.02.070","article-title":"Pathologist characteristics associated with accuracy and reproducibility of melanocytic skin lesion interpretation.","volume":"79","author":"Elder","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"doi230054r18","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1111\/cup.13265","article-title":"Influence of variability in assessment of Breslow thickness, mitotic rate and ulceration among US pathologists interpreting invasive melanoma, for the purpose of AJCC staging.","volume":"45","author":"Taylor","year":"2018","journal-title":"J Cutan Pathol"},{"issue":"10","key":"doi230054r19","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1001\/jamadermatol.2018.2388","article-title":"Accuracy of digital pathologic analysis vs traditional microscopy in the interpretation of melanocytic lesions.","volume":"154","author":"Onega","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"10","key":"doi230054r20","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/cup.12751","article-title":"Achieving consensus for the histopathologic diagnosis of melanocytic lesions: use of the modified Delphi method.","volume":"43","author":"Carney","year":"2016","journal-title":"J Cutan Pathol"},{"issue":"1","key":"doi230054r21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/cncr.34490","article-title":"Prognostic modeling of cutaneous melanoma stage I patients using cancer registry data identifies subsets with very-low melanoma mortality.","volume":"129","author":"Eguchi","year":"2023","journal-title":"Cancer"},{"issue":"7","key":"doi230054r23","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.amjmed.2017.01.026","article-title":"Where have the generalists gone? they became specialists, then subspecialists.","volume":"130","author":"Dalen","year":"2017","journal-title":"Am J Med"},{"issue":"6","key":"doi230054r24","doi-asserted-by":"crossref","first-page":"559","DOI":"10.4065\/72.6.559","article-title":"The melanoma epidemic: more apparent than real?","volume":"72","author":"Swerlick","year":"1997","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"doi230054r25","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.pathol.2022.12.345","article-title":"Diagnostic error, uncertainty, and overdiagnosis in melanoma.","volume":"55","author":"Elder","year":"2023","journal-title":"Pathology"},{"issue":"7515","key":"doi230054r26","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1136\/bmj.38516.649537.E0","article-title":"Skin biopsy rates and incidence of melanoma: population based ecological study.","volume":"331","author":"Welch","year":"2005","journal-title":"BMJ"},{"issue":"6","key":"doi230054r27","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/jamadermatol.2022.0489","article-title":"Dermatopathologist perceptions of overdiagnosis of melanocytic skin lesions and association with diagnostic behaviors.","volume":"158","author":"Kerr","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi230054r28","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jamadermatol.2022.0082","article-title":"Melanoma screening\u2014intuition and hope are not enough.","volume":"158","author":"Swerlick","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi230054r29","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/jnci\/djac195","article-title":"Re: obligate and potential precursors of melanoma.","volume":"115","author":"Swerlick","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"doi230054r30","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/ajcp\/aqaa088","article-title":"Malpractice and patient safety concerns.","volume":"154","author":"Reisch","year":"2020","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"doi230054r31","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/archpediatrics.2009.31","article-title":"The relative merits of risk ratios and odds ratios.","volume":"163","author":"Cummings","year":"2009","journal-title":"Arch Pediatr Adolesc Med"},{"issue":"7136","key":"doi230054r32","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/bmj.316.7136.989","article-title":"When can odds ratios mislead?","volume":"316","author":"Davies","year":"1998","journal-title":"BMJ"},{"issue":"2. Pt 1","key":"doi230054r33","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/01.AOG.0000297304.32187.5d","article-title":"Making sense of odds and odds ratios.","volume":"111","author":"Grimes","year":"2008","journal-title":"Obstet Gynecol"},{"key":"doi230054r15","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017","edition":"8th ed"},{"key":"doi230054r22","author":"Elder","year":"2018"},{"key":"doi230054r14","doi-asserted-by":"crossref","unstructured":"Elmore? JG, Elder? DE, Barnhill? RL, . Concordance and reproducibility of melanoma staging according to the 7th vs 8th edition of the AJCC Cancer Staging Manual. JAMA Netw Open. 2018;1(1):e180083. doi:10.1001\/jamanetworkopen.2018.0083","DOI":"10.1001\/jamanetworkopen.2018.0083"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2811788\/jamadermatology_kerr_2023_oi_230054_1701809828.07799.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T16:03:37Z","timestamp":1703088217000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2811788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.4334","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,1]]}}}